Ensysce Biosciences (ENSC)
NASDAQ:ENSC
Want to see ENSC full AI Analyst Report?
ENSC Stock Chart & Stats
$1.01
-$0.28(-3.41%)
At close: 4:00 PM EST
$1.01
-$0.28(-3.41%)
Day’s Range― - ―
52-Week Range$0.23 - $2.75
Previous CloseN/A
Volume52.20K
Average Volume (3M)89.63K
Market Cap
$4.13M
Enterprise Value$2.11M
Total Cash (Recent Filing)$745.48K
Total Debt (Recent Filing)$245.85K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 19, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.35
Shares Outstanding14,694,492
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.46
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue0.75
Enterprise Value/Gross Profit-1.02
Enterprise Value/Ebitda-0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.54
Revenue Forecast (FY)$7.70M
Bulls Say, Bears Say
Bulls Say
Proprietary Abuse-deterrent Technologies (TAAP, MPAR)Ensysce’s proprietary TAAP and MPAR platforms create a durable product differentiation in opioid analgesics. Structural demand for safer, abuse‑resistant opioids and regulatory emphasis on overdose mitigation support long‑term commercial and partnership potential versus generic alternatives.
Committed Private Financing Line Supports RunwayA $2M close plus a committed tranche up to $20M materially extends near‑term runway without a public equity raise. For a clinical‑stage biotech, secured private funding reduces immediate refinancing pressure and allows continued clinical execution and milestone advancement.
Improving Free Cash Flow TrendYear‑over‑year improvement in free cash flow indicates progress in cost control and cash management. While still negative, an improving cash flow trajectory is a durable sign management is narrowing cash burn and extending operational flexibility between financings.
Bears Say
Negative Equity And Weak CapitalizationNegative equity signals cumulative losses and a fragile capital base, limiting borrowing capacity and strategic optionality. This structural weakness increases dependency on dilutive financing, raising long‑term shareholder dilution risk and constraining growth investments.
Persistent Cash Burn And Negative Operating Cash FlowSustained negative operating cash flow (~$9.6M TTM) reflects ongoing cash consumption to fund R&D and operations. Continued burn requires repeated external capital infusions, making program continuity and execution contingent on successful future financings.
Deep Unprofitability And Declining RevenueSteep negative margins and a 26% TTM revenue decline underscore the absence of recurring commercial revenue. For a clinical‑stage biotech, volatile revenue and extreme unprofitability reduce resilience to shocks and lengthen the timeline to a sustainable, non‑dilutive business model.
Ensysce Biosciences News
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $0.23 and its highest was $2.75 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $4.13M.
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is Aug 19, 2026 which is in 80 days.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on May 18, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.73 by $0.21.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate is -0.5.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 14,694,492 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.73. Following the earnings report the stock price went up 13.214%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ensysce Biosciences
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Technical Analysis
Ownership Overview
―
Insiders
0.23% Mutual Funds
1.72% Other Institutional Investors
97.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---